|
1
|
Campo E, Swerdlow SH, Harris NL, Pileri S,
Stein H and Jaffe ES: The 2008 WHO classification of lymphoid
neoplasms and beyond: Evolving concepts and practical applications.
Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vose J, Armitage J and Weisenburger D:
International T-Cell Lymphoma Project: International peripheral
T-cell and natural killer/T-cell lymphoma study: Pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitrovic Z, Perry AM, Suzumiya J, Armitage
JO, Au WY, Coiffier B, Holte H, Jaffe ES, Monserrat E, Rajan SK, et
al: The prognostic significance of lymphopenia in peripheral T-cell
and natural killer/T-cell lymphomas: A study of 826 cases from the
International Peripheral T-cell Lymphoma Project. Am J Hematol.
87:790–794. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jo JC, Yoon DH, Kim S, Lee BJ, Jang YJ,
Park CS, Huh J, Lee SW, Ryu JS and Suh C: Clinical features and
prognostic model for extranasal NK/T-cell lymphoma. Eur J Haematol.
89:103–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS
and Kim SW: Clinicopathologic and genotypic study of extranodal
nasal-type natural killer/T-cell lymphoma and natural killer
precursor lymphoma among Koreans. Cancer. 89:2106–2116. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suzuki R: NK/T-cell lymphomas:
Pathobiology, prognosis and treatment paradigm. Curr Oncol Rep.
14:395–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kawa K: Epstein-Barr virus-associated
diseases in humans. Int J Hematol. 71:108–117. 2000.PubMed/NCBI
|
|
8
|
Oshimi K: Progress in understanding and
managing natural killer-cell malignancies. Br J Haematol.
139:532–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park S and Ko YH: Epstein-Barr
virus-associated T/natural killer-cell lymphoproliferative
disorders. J Dermatol. 41:29–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garady C, Saieg MA, Ko HM, Geddie WR,
Boerner SL and da Cunha Santos G: Epstein-Barr virus encoded RNA
detected by in situ hybridization using cytological preparations.
Cytopathology. 25:101–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the world health organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zelenetz AD, Gordon LI, Wierda WG,
Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd
JC, Czuczman MS, et al: Non-Hodgkin's lymphomas, version 2.2014. J
Natl Compr Canc Netw. 12:916–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project, . A predictive model for aggressive
Non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kwong YL, Pang AW, Leung AY, Chim CS and
Tse E: Quantification of circulating Epstein-Barr virus DNA in
NK/T-cell lymphoma treated with the SMILE protocol: Diagnostic and
prognostic significance. Leukemia. 28:865–870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong J, Park S, Baek HL, Jung JH, Kang IG,
Sym SJ, Park J, Ahn JY, Cho EK, Kim ST, et al: Tumor cell nuclear
diameter and CD30 expression as potential prognostic parameter in
patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin
Exp Pathol. 5:939–947. 2012.PubMed/NCBI
|
|
16
|
Krenacs L, Smyth MJ, Bagdi E, Krenacs T,
Kopper L, Rudiger T, Zettl A, Muller-Hermelink HK, Jaffe ES and
Raffeld M: The serine protease granzyme M is preferentially
expressed in NK-cell, gamma delta T-cell, and intestinal T-cell
lymphomas: Evidence of origin from lymphocytes involved in innate
immunity. Blood. 101:3590–3593. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taylor GS, Long HM, Brooks JM, Rickinson
AB and Hislop AD: The immunology of Epstein-Barr virus-induced
disease. Annu Rev Immunol. 33:787–821. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bajor-Dattilo EB, Pittaluga S and Jaffe
ES: Pathobiology of T-cell and NK-cell lymphomas. Best Pract Res
Clin Haematol. 26:75–87. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai Q, Chen K and Young KH: Epstein-Barr
virus-positive T/NK-cell lymphoproliferative disorders. Exp Mol
Med. 47:e1332015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuling H, Ruijing X, Li L, Xiang J, Rui Z,
Yujuan W, Lijun Z, Chunxian D, Xinti T, Wei X, et al: EBV-induced
human CD8+ NKT cells suppress tumorigenesis by EBV-associated
malignancies. Cancer Res. 69:7935–7944. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang RC, Chang ST, Hsieh YC, Huang WT, Hsu
JD, Tseng CE, Wang MC, Hwang WS, Wang J and Chuang SS: Spectrum of
Epstein-Barr virus-associated T-cell lymphoproliferative disorder
in adolescents and young adults in Taiwan. Int J Clin Exp Pathol.
7:2430–2437. 2014.PubMed/NCBI
|
|
22
|
Liaw CC, Chen JS, Wang CH, Chang HK and
Huang JS: Tumor fever in patients with nasopharyngeal carcinoma:
Clinical experience of 67 patients. Am J Clin Oncol. 21:422–425.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim TM, Park YH, Lee SY, Kim JH, Kim DW,
Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, et al: Local tumor
invasiveness is more predictive of survival than international
prognostic index in stage I(E)/II(E) extranodal NK/T-cell lymphoma,
nasal type. Blood. 106:3785–3790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mazodier K, Marin V, Novick D, Farnarier
C, Robitail S, Schleinitz N, Veit V, Paul P, Rubinstein M,
Dinarello CA, et al: Severe imbalance of IL-18/IL-18BP in patients
with secondary hemophagocytic syndrome. Blood. 106:3483–3489. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kimura H, Hoshino Y, Hara S, Sugaya N,
Kawada J, Shibata Y, Kojima S, Nagasaka T, Kuzushima K and
Morishima T: Differences between T cell-type and natural killer
cell-type chronic active Epstein-Barr virus infection. J Infect
Dis. 191:531–539. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chuang HC, Lay JD, Chuang SE, Hsieh WC,
Chang Y and Su IJ: Epstein-Barr virus (EBV) latent membrane
protein-1 down-regulates tumor necrosis factor-alpha (TNF-alpha)
receptor-1 and confers resistance to TNF-alpha-induced apoptosis in
T cells: Implication for the progression to T-cell lymphoma in
EBV-associated hemophagocytic syndrome. Am J Pathol. 170:1607–1617.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang QP, Liu SY, Yang YX, Tan XX, Peng J,
Xiong ZT and Li Z: CD20-positive NK/T-cell lymphoma with indolent
clinical course: Report of case and review of literature. Diagn
Pathol. 7:1332012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gill HS, Lau WH, Chan AC, Leung RY, Khong
PL, Leung AY and Kwong YL: CD20 expression in natural killer T cell
lymphoma. Histopathology. 57:157–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang YH, Huang CT, Tan SY and Chuang SS:
Primary gastric extranodal natural killer/T-cell lymphoma, nasal
type, with acquisition of CD20 expression in the subcutaneous
relapse: Report of a case with literature review. J Clin Pathol.
68:943–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chuang WY, Chang H, Shih LY, Wang PN,
Chang YS, Lin TL, Hung YS, Yeh CJ, Ueng SH, Tang TC, et al: CD5
positivity is an independent adverse prognostic factor in elderly
patients with diffuse large B cell lymphoma. Virchows Arch.
467:571–582. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wada T, Sakakibara Y, Nishimura R, Toma T,
Ueno Y, Horita S, Tanaka T, Nishi M, Kato K, Yasumi T, et al:
Down-regulation of CD5 expression on activated CD8+ T cells in
familial hemophagocytic lymphohistiocytosis with perforin gene
mutations. Hum Immunol. 74:1579–1585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Karsan A, Gascoyne RD, Coupland RW,
Shepherd JD, Phillips GL and Horsman DE: Combination of t(14;18)
and a Burkitt's type translocation in B-cell malignancies. Leuk
Lymphoma. 10:433–441. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adida C, Haioun C, Gaulard P, Lepage E,
Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C,
et al: Prognostic significance of survivin expression in diffuse
large B-cell lymphomas. Blood. 96:1921–1925. 2000.PubMed/NCBI
|
|
34
|
Lu R, Jiang M, Chen Z, Xu X, Hu H, Zhao X,
Gao X and Guo L: Lactate dehydrogenase 5 expression in Non-Hodgkin
lymphoma is associated with the induced hypoxia regulated protein
and poor prognosis. PLoS One. 8:e748532013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Serganova I, Rizwan A, Ni X, Thakur SB,
Vider J, Russell J, Blasberg R and Koutcher JA: Metabolic imaging:
A link between lactate dehydrogenase A, lactate, and tumor
phenotype. Clin Cancer Res. 17:6250–6261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised international prognostic index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Buske C, Hoster E, Dreyling M, Hasford J,
Unterhalt M and Hiddemann W: The follicular lymphoma international
prognostic index (FLIPI) separates high-risk from intermediate- or
low-risk patients with advanced-stage follicular lymphoma treated
front-line with rituximab and the combination of cyclophosphamide,
doxorubicin, vincristine, and prednisone (R-CHOP) with respect to
treatment outcome. Blood. 108:1504–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tomita N, Taguri M, Hashimoto C, Takasaki
H, Fujimaki K, Motomura S, Koharazawa H, Takemura S, Fujita H,
Yamazaki E, et al: Evaluation of soluble interleukin-2 receptor and
serum lactate dehydrogenase in malignant lymphoma. Ann Hematol.
94:1935–1937. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chauchet A, Michallet AS, Berger F,
Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront
B, Petrella T, et al: Complete remission after first-line
radio-chemotherapy as predictor of survival in extranodal NK/T cell
lymphoma. J Hematol Oncol. 5:272012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dearden CE, Johnson R, Pettengell R,
Devereux S, Cwynarski K, Whittaker S and McMillan A: British and
Committee for Standards in Haematology: Guidelines for the
management of mature T-cell and NK-cell neoplasms (excluding
cutaneous T-cell lymphoma). Br J Haematol. 153:451–485. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zelenetz AD, Abramson JS, Advani RH,
Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ,
Gockerman JP, et al: NCCN clinical practice guidelines in oncology:
Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 8:288–334. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kwong YL: Natural killer-cell
malignancies: Diagnosis and treatment. Leukemia. 19:2186–2194.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheung MM, Chan JK and Wong KF: Natural
killer cell neoplasms: A distinctive group of highly aggressive
lymphomas/leukemias. Semin Hematol. 40:221–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Federico M, Rudiger T, Bellei M, Nathwani
BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage
KJ, et al: Clinicopathologic characteristics of angioimmunoblastic
T-Cell lymphoma: Analysis of the international peripheral T-cell
lymphoma project. J Clin Oncol. 31:240–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang ZY, Liu QF, Wang H, Jin J, Wang WH,
Wang SL, Song YW, Liu YP, Fang H, Ren H, et al: Clinical
implications of plasma Epstein-Barr virus DNA in early-stage
extranodal nasal-type NK/T-cell lymphoma patients receiving primary
radiotherapy. Blood. 120:2003–2010. 2012. View Article : Google Scholar : PubMed/NCBI
|
